Pulmatrix Total Assets 2014-2021 | PULM

Pulmatrix total assets from 2014 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Pulmatrix Annual Total Assets
(Millions of US $)
2020 $38
2019 $36
2018 $15
2017 $16
2016 $17
2015 $45
2014 $2
2014 $16
2013 $-0
2013 $0
2012 $0
Pulmatrix Quarterly Total Assets
(Millions of US $)
2021-09-30 $56
2021-06-30 $65
2021-03-31 $70
2020-12-31 $38
2020-09-30 $43
2020-06-30 $35
2020-03-31 $31
2019-12-31 $36
2019-09-30 $33
2019-06-30 $37
2019-03-31 $14
2018-12-31 $15
2018-09-30 $16
2018-06-30 $21
2018-03-31 $14
2017-12-31 $16
2017-09-30 $19
2017-06-30 $24
2017-03-31 $23
2016-12-31 $17
2016-09-30 $25
2016-06-30 $29
2016-03-31 $40
2015-12-31 $45
2015-09-30 $48
2015-06-30 $50
2015-03-31 $0
2014-12-31 $2
2014-09-30 $13
2014-06-30 $15
2014-03-31 $16
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.035B $0.013B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $122.991B 7.77
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.439B 21.07
Biohaven Pharmaceutical Holding (BHVN) United States $7.159B 0.00
Arcus Biosciences (RCUS) United States $3.161B 0.00
Emergent Biosolutions (EBS) United States $2.298B 8.26
ADC Therapeutics SA (ADCT) Switzerland $1.545B 0.00
Myovant Sciences (MYOV) United Kingdom $1.443B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.348B 0.00
SQZ Biotechnologies (SQZ) United States $0.329B 0.00
Enzo Biochem (ENZ) United States $0.163B 16.00